Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling.

Biological effects of small molecules in an organism result from favorable interactions between the molecules and their target proteins. These interactions depend on chemical functionalities, bonds, and their 3D-orientations towards each other. These 3D-arrangements of chemical functionalities that make a small molecule active towards its target can be described by pharmacophore models. In these models, chemical functionalities are represented as so-called features. Commonly, they are obtained either from a set of active compounds or directly from the observed protein-ligand interactions as present in X-ray crystal structures, NMR structures, or docking poses. In this review, we explain the basics of pharmacophore modeling including dataset generation, 3D-representations and conformational analysis of small molecules, pharmacophore model construction, model validation, and its benefits to virtual screening and other applications.

[1]  Carolina H Andrade,et al.  Assessing the performance of 3D pharmacophore models in virtual screening: how good are they? , 2013, Current topics in medicinal chemistry.

[2]  V. Zoete,et al.  Identification of Human IKK-2 Inhibitors of Natural Origin (Part I): Modeling of the IKK-2 Kinase Domain, Virtual Screening and Activity Assays , 2011, PloS one.

[3]  Andrzej J. Bojarski,et al.  New Strategy for Receptor-Based Pharmacophore Query Construction: A Case Study for 5-HT7 Receptor Ligands , 2013, J. Chem. Inf. Model..

[4]  Li Di,et al.  Biological assay challenges from compound solubility: strategies for bioassay optimization. , 2006, Drug discovery today.

[5]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[6]  Yanli Wang,et al.  PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..

[7]  Andrew Smellie,et al.  Analysis of Conformational Coverage, 1. Validation and Estimation of Coverage , 1995, J. Chem. Inf. Comput. Sci..

[8]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[9]  David E. Shaw,et al.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..

[10]  David J Diller,et al.  Deriving knowledge through data mining high-throughput screening data. , 2004, Journal of medicinal chemistry.

[11]  Kai Huang,et al.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..

[12]  Jiabo Li,et al.  CAESAR: A New Conformer Generation Algorithm Based on Recursive Buildup and Local Rotational Symmetry Consideration , 2007, J. Chem. Inf. Model..

[13]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[14]  Y. Kurogi,et al.  Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. , 2001, Current medicinal chemistry.

[15]  B. Shoichet,et al.  Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.

[16]  Andrew Smellie,et al.  Analysis of Conformational Coverage, 2. Applications of Conformational Models , 1995, J. Chem. Inf. Comput. Sci..

[17]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[18]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[19]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[20]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[21]  W. Kabsch.  A solution for the best rotation to relate two sets of vectors , 1976 .

[22]  Robert J Kavlock,et al.  Toxicity Testing in the 21st Century: Implications for Human Health Risk Assessment , 2009, Risk analysis : an official publication of the Society for Risk Analysis.

[23]  Marvin Waldman,et al.  Optimization and visualization of molecular diversity of combinatorial libraries , 1996, Molecular Diversity.

[24]  Klaus R. Liedl,et al.  One Concept, Three Implementations of 3D Pharmacophore-Based Virtual Screening: Distinct Coverage of Chemical Search Space , 2010, J. Chem. Inf. Model..

[25]  Daniela Schuster,et al.  Pharmacophore Model Refinement for 11β‐Hydroxysteroid Dehydrogenase Inhibitors: Search for Modulators of Intracellular Glucocorticoid Concentrations , 2014, Molecular informatics.

[26]  Thomas Seidel,et al.  Strategies for 3D pharmacophore-based virtual screening. , 2010, Drug discovery today. Technologies.

[27]  V. Cerný.  Thermodynamical approach to the traveling salesman problem: An efficient simulation algorithm , 1985 .

[28]  Camille G Wermuth,et al.  Selective optimization of side activities: the SOSA approach. , 2006, Drug discovery today.

[29]  Barry M. Twenter,et al.  Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. , 2012, Bioorganic & medicinal chemistry letters.

[30]  Barend Mons,et al.  Open PHACTS: semantic interoperability for drug discovery. , 2012, Drug discovery today.

[31]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[32]  D. Ferguson,et al.  A new approach to probing conformational space with molecular mechanics: Random incremental pulse search , 1989 .

[33]  A. Mittal,et al.  Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity. , 2014, Bioorganic & Medicinal Chemistry Letters.

[34]  C. Wermuth,et al.  Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) , 1998 .

[35]  Hualiang Jiang,et al.  Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation. , 2012, Journal of medicinal chemistry.

[36]  Raffaella Corvi,et al.  How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. , 2007, Mutation research.

[37]  Osman F. Güner,et al.  Pharmacophore perception, development, and use in drug design , 2000 .

[38]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[39]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[40]  Daniela Schuster,et al.  Ligand-Based Pharmacophore Modeling and Virtual Screening for the Discovery of Novel 17β-Hydroxysteroid Dehydrogenase 2 Inhibitors , 2014, Journal of medicinal chemistry.

[41]  Kathrin Heikamp,et al.  Comparison of Confirmed Inactive and Randomly Selected Compounds as Negative Training Examples in Support Vector Machine-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[42]  Shahnaz Perveen,et al.  Identification of potent urease inhibitors via ligand- and structure-based virtual screening and in vitro assays. , 2010, Journal of molecular graphics & modelling.

[43]  G. Hessler,et al.  The scaffold hopping potential of pharmacophores. , 2010, Drug discovery today. Technologies.

[44]  Andrew G. Glen,et al.  APPL , 2001 .

[45]  Pekka Tiikkainen,et al.  Estimating Error Rates in Bioactivity Databases , 2013, J. Chem. Inf. Model..

[46]  Thierry Langer,et al.  The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. , 2006, Journal of medicinal chemistry.

[47]  F. Russel,et al.  In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors. , 2014, Chemical research in toxicology.

[48]  Zhi Chen,et al.  Multiple Pharmacophore Models Combined with Molecular Docking: A Reliable Way for Efficiently Identifying Novel PDE4 Inhibitors with High Structural Diversity , 2010, J. Chem. Inf. Model..

[49]  Thierry Langer,et al.  Efficient overlay of small organic molecules using 3D pharmacophores , 2007, J. Comput. Aided Mol. Des..

[50]  Jonas Boström,et al.  Reproducing the conformations of protein-bound ligands: A critical evaluation of several popular conformational searching tools , 2001, J. Comput. Aided Mol. Des..

[51]  Richard A. Lewis,et al.  Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.

[52]  W. Pao,et al.  Mechanism for activation of mutated epidermal growth factor receptors in lung cancer , 2013, Proceedings of the National Academy of Sciences.

[53]  Thierry Langer,et al.  Development and validation of an in silico P450 profiler based on pharmacophore models. , 2006, Current drug discovery technologies.

[54]  Steven L Dixon,et al.  PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching , 2006, Chemical biology & drug design.

[55]  Jong Young Joung,et al.  Identification of Novel Rab27a/Melanophilin Blockers by Pharmacophore-Based Virtual Screening , 2013, Applied Biochemistry and Biotechnology.

[56]  O. Werz,et al.  Pharmacophore Modeling and Virtual Screening for Novel Acidic Inhibitors of Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) , 2011, Journal of medicinal chemistry.

[57]  Simona Distinto,et al.  How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..

[58]  Andreas Evers,et al.  Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. , 2009, Journal of medicinal chemistry.

[59]  J. Dearden,et al.  QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.

[60]  Ruth Nussinov,et al.  PharmaGist: a webserver for ligand-based pharmacophore detection , 2008, Nucleic Acids Res..

[61]  Yu-Quan Wei,et al.  Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[62]  M. Negri,et al.  Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization. , 2013, Journal of medicinal chemistry.

[63]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[64]  Anthony Nicholls,et al.  Conformer Generation with OMEGA: Learning from the Data Set and the Analysis of Failures , 2012, J. Chem. Inf. Model..

[65]  C. Sotriffer,et al.  Docking compared to 3D-pharmacophores: the scoring function challenge , 2010 .

[66]  Yan Niu,et al.  The Discovery of Novel β‐Secretase Inhibitors: Pharmacophore Modeling, Virtual Screening, and Docking Studies , 2012, Chemical biology & drug design.

[67]  P. Wipf,et al.  Stochastic voyages into uncharted chemical space produce a representative library of all possible drug-like compounds. , 2013, Journal of the American Chemical Society.

[68]  Jin Hwan Kim,et al.  Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules , 2003, Nature.

[69]  J. Bajorath,et al.  Learning from 'big data': compounds and targets. , 2014, Drug discovery today.

[70]  Thierry Langer,et al.  Pharmacophore modeling and parallel screening for PPAR ligands , 2007, J. Comput. Aided Mol. Des..

[71]  Nicolas Foloppe,et al.  Conformational Sampling of Druglike Molecules with MOE and Catalyst: Implications for Pharmacophore Modeling and Virtual Screening , 2008, J. Chem. Inf. Model..

[72]  Gerhard Klebe,et al.  Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..

[73]  Peter W Swaan,et al.  Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening. , 2013, Molecular pharmaceutics.

[74]  Jonas Boström,et al.  Computational chemistry-driven decision making in lead generation. , 2006, Drug discovery today.

[75]  Benjamin A. Ellingson,et al.  Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..

[76]  Peter Ertl,et al.  Intuitive Ordering of Scaffolds and Scaffold Similarity Searching Using Scaffold Keys , 2014, J. Chem. Inf. Model..

[77]  Thierry Langer,et al.  In silico Target Fishing for Rationalized Ligand Discovery Exemplified on Constituents of Ruta graveolens , 2008, Planta medica.

[78]  Sandra Fox,et al.  High-Throughput Screening: Update on Practices and Success , 2006, Journal of biomolecular screening.

[79]  Christof H. Schwab,et al.  Conformations and 3D pharmacophore searching. , 2010, Drug discovery today. Technologies.

[80]  H. Kuhn.  The Hungarian method for the assignment problem , 1955 .

[81]  Woody Sherman,et al.  Novel Method for Generating Structure-Based Pharmacophores Using Energetic Analysis , 2009, J. Chem. Inf. Model..

[82]  Thierry Langer,et al.  Comparative Analysis of Protein-Bound Ligand Conformations with Respect to Catalyst's Conformational Space Subsampling Algorithms , 2005, J. Chem. Inf. Model..

[83]  James E. J. Mills,et al.  Enhanced HTS Hit Selection via a Local Hit Rate Analysis , 2009, J. Chem. Inf. Model..

[84]  J. A. Grant,et al.  A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..

[85]  Daniela Schuster,et al.  Discovery of New Liver X Receptor Agonists by Pharmacophore Modeling and Shape-Based Virtual Screening , 2014, J. Chem. Inf. Model..

[86]  T. Maung.  on in C , 2010 .

[87]  H. Ke,et al.  Multiple Conformations of Phosphodiesterase-5 , 2006, Journal of Biological Chemistry.

[88]  Thierry Langer,et al.  Comparative Performance Assessment of the Conformational Model Generators Omega and Catalyst: A Large-Scale Survey on the Retrieval of Protein-Bound Ligand Conformations , 2006, J. Chem. Inf. Model..

[89]  A. Warshel,et al.  Consistent Force Field for Calculations of Conformations, Vibrational Spectra, and Enthalpies of Cycloalkane and n‐Alkane Molecules , 1968 .

[90]  S. Ahn,et al.  Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening. , 2011, Bioorganic & medicinal chemistry letters.

[91]  Jiabo Li,et al.  New features that improve the pharmacophore tools from Accelrys. , 2011, Current computer-aided drug design.

[92]  Anna Tramontano,et al.  The PMDB Protein Model Database , 2005, Nucleic Acids Res..

[93]  Ruth Nussinov,et al.  Novel Approach for Efficient Pharmacophore-Based Virtual Screening: Method and Applications , 2009, J. Chem. Inf. Model..

[94]  F. Lichtenthaler.  100 Years “Schlüssel‐Schloss‐Prinzip”: What Made Emil Fischer Use this Analogy? , 1995 .

[95]  Jihyun Park,et al.  Identification and Validation of Novel PERK Inhibitors , 2014, J. Chem. Inf. Model..

[96]  Jacob de Vlieg,et al.  Comparative Analysis of Pharmacophore Screening Tools , 2012, J. Chem. Inf. Model..

[97]  T. Langer,et al.  Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors. , 2010, Bioorganic & medicinal chemistry.

[98]  David A. Dixon,et al.  Annual reports in computational chemistry , 2007 .

[99]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[100]  Daniela Schuster,et al.  Pharmacophore-based discovery of a novel cytosolic phospholipase A2α inhibitor , 2012, Bioorganic & medicinal chemistry letters.

[101]  D. Bernhard,et al.  Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein , 2011, Atherosclerosis.

[102]  Thierry Langer,et al.  The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals. , 2010, Biochemical pharmacology.

[103]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[104]  Daniela Schuster,et al.  3D pharmacophores as tools for activity profiling. , 2010, Drug discovery today. Technologies.

[105]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[106]  Daniela Schuster,et al.  Pharmacophore Modeling, Virtual Screening, and in Vitro Testing Reveal Haloperidol, Eprazinone, and Fenbutrazate as Neurokinin Receptors Ligands , 2014, J. Chem. Inf. Model..

[107]  Andrew Smellie,et al.  Identification of Common Functional Configurations Among Molecules , 1996, J. Chem. Inf. Comput. Sci..

[108]  Chris de Graaf,et al.  Snooker: A Structure-Based Pharmacophore Generation Tool Applied to Class A GPCRs , 2011, J. Chem. Inf. Model..

[109]  Woody Sherman,et al.  ConfGen: A Conformational Search Method for Efficient Generation of Bioactive Conformers , 2010, J. Chem. Inf. Model..

[110]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[111]  Thierry Langer,et al.  Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models , 2007, J. Chem. Inf. Model..

[112]  Rahul P Gangwal,et al.  Identification of p38α MAP kinase inhibitors by pharmacophore based virtual screening. , 2014, Journal of molecular graphics & modelling.

[113]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[114]  J. A. Grant,et al.  A Gaussian Description of Molecular Shape , 1995 .

[115]  P. Ehrlich.  Über den jetzigen Stand der Chemotherapie , 1909 .

[116]  Tao Jiang,et al.  ChemmineR: a compound mining framework for R , 2008, Bioinform..

[117]  David A Sivak,et al.  Crystal cryocooling distorts conformational heterogeneity in a model Michaelis complex of DHFR. , 2014, Structure.

[118]  J. Pin,et al.  Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. , 2005, Journal of medicinal chemistry.

[119]  David Ryan Koes,et al.  Pharmer: Efficient and Exact Pharmacophore Search , 2011, J. Chem. Inf. Model..

[120]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[121]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[122]  Thierry Langer,et al.  Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. , 2008, Journal of medicinal chemistry.

[123]  J. Gasteiger,et al.  FROM ATOMS AND BONDS TO THREE-DIMENSIONAL ATOMIC COORDINATES : AUTOMATIC MODEL BUILDERS , 1993 .

[124]  Thierry Langer,et al.  Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening , 2006, J. Chem. Inf. Model..